Strategies aimed at lowering HTT protein levels, by targeting either the huntingtin gene or the transcript, have become a major focus of therapeutic development for Huntington’s disease (Tabrizi et al., 2019a), with antisense oligonucleotides having progressed to a phase 3 clinical trial (Tabrizi et al., 2019b). Here, HTT is linked to juvenile Huntington disease.